Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · Real-Time Price · USD
1.960
-0.010 (-0.51%)
At close: Nov 13, 2026, 4:00 PM EST
1.930
-0.030 (-1.53%)
After-hours: Nov 13, 2026, 7:30 PM EST
PACB Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, PACB stock has a consensus rating of "Buy" and an average price target of $2.74. The average 1-year stock price forecast is 39.95% higher than the current stock price, while the lowest is $2.00 (+2.04%) and the highest is $3.00 (+53.06%).
Price Target: $2.74 (+39.95%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for PACB stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Reiterates $3.05 → $2.7 | Hold | Reiterates | $3.05 → $2.7 | +37.76% | Nov 9, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $3 | Buy | Maintains | $3 | +53.06% | Nov 5, 2026 |
| Piper Sandler | Piper Sandler | Hold Reiterates $2 → $3 | Hold | Reiterates | $2 → $3 | +53.06% | Nov 5, 2026 |
| Barclays | Barclays | Sell Maintains $1.25 → $2 | Sell | Maintains | $1.25 → $2 | +2.04% | Nov 5, 2026 |
| Stephens | Stephens | Buy Maintains $1.5 → $2.5 | Buy | Maintains | $1.5 → $2.5 | +27.55% | Oct 23, 2026 |
Financial Forecast
Revenue This Year
157.40M
from 160.01M
Decreased by -1.63%
Revenue Next Year
179.47M
from 157.40M
Increased by 14.03%
EPS This Year
-0.49
from -0.53
EPS Next Year
-0.41
from -0.49
EPS and Forward PE are based on non-GAAP adjusted numbers.